Phase II, Open Label, Dose Finding Study of the Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer Compared to a Luteinizing Hormone Releasing Hormone Agonist.

Trial Profile

Phase II, Open Label, Dose Finding Study of the Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer Compared to a Luteinizing Hormone Releasing Hormone Agonist.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2015

At a glance

  • Drugs GTx 758 (Primary) ; Leuprorelin
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors GTx
  • Most Recent Events

    • 08 May 2013 Tolerability outcomes presented at the 108th Annual Meeting of the American Urological Association.
    • 19 Mar 2013 Results presented at the 28th Annual European Association of urology Congress, according to a GTx media release.
    • 13 Feb 2013 Results will be presented at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium according to a GTx media release. Results were also briefly summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top